


PRODUCT: GSK-1838705A

ALTERNATE NAMES: 2-((2-((1-(2-(dimethylamino)acetyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide

CATALOG NUMBER: B2026-1,5

AMOUNT: 1 mg, 5 mg

STRUCTURE:

MOLECULAR FORMULA: C₂₇H₂₉N₈O₃

MOLECULAR WEIGHT: 532.57

CAS NUMBER: 1116235-97-2

APPEARANCE: Beige solid

SOLUBILITY: DMSO

PURITY: ≥98% by HPLC

STORAGE: Store at -20 °C. Protect from air and light

DESCRIPTION: GSK-1838705A is a potent small-molecule kinase inhibitor that inhibits IGF-IR and IR (insulin receptor) with IC₅₀s of 2.0 and 1.6 nM, respectively. It also inhibits anaplastic lymphoma kinase (ALK). It causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses.

REFERENCES: Sabbatini, P., *et al.* (2009). *Mol. Cancer Ther.* **8**, 2811-2820

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

A 83-01 (**1725**)
EZSolution™ A 83-01 (**1989**)
ASP-3026 (**B1296**)
AZD-3463 (**2371**)
Brigatinib (AP26113) (**9675**)
Brigatinib Analog (**B2025**)
CH5424802 (**2867**)
Crizotinib (**1934**)
Ensartinib (**B1946**)
Entrectinib (**B1324**)
GSK-1838705A (**B2026**)
LDK-378 (**B1928**)
NVP-TAE684 (**1683**)
PF-06463922 (**B1169**)
SU-5416 (**9491**)

USAGE: **FOR RESEARCH USE ONLY! Not to be used in humans**